Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Irinotecan (Primary)
  • Indications Ewing's sarcoma; Hepatoblastoma; Neuroblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 16 Dec 2021 The trial has been completed in Poland, Germany and Italy. Ongoing in Spain and no longer in UK according to European Clinical Trials Database record. Trial status is as per NCT
    • 26 Jul 2021 Status changed from recruiting to completed.
    • 31 May 2020 Results (data cut-off: July 14, 2019) presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top